These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 23603977

  • 1. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
    Wang WJ, Long LM, Yang N, Zhang QQ, Ji WJ, Zhao JH, Qin ZH, Wang Z, Chen G, Liang ZQ.
    Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977
    [Abstract] [Full Text] [Related]

  • 2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S, Flentje M, Djuzenova CS.
    Radiat Oncol; 2015 Oct 24; 10():214. PubMed ID: 26498922
    [Abstract] [Full Text] [Related]

  • 4. Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis.
    Ye H, Chen M, Cao F, Huang H, Zhan R, Zheng X.
    BMC Neurol; 2016 Sep 20; 16(1):178. PubMed ID: 27644442
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Sep 20; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, Maity A.
    Mol Pharmacol; 2012 Dec 20; 82(6):1230-40. PubMed ID: 22989521
    [Abstract] [Full Text] [Related]

  • 7. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.
    Mol Cancer Ther; 2009 Aug 20; 8(8):2204-10. PubMed ID: 19671762
    [Abstract] [Full Text] [Related]

  • 8. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
    Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.
    Radiat Oncol; 2012 Mar 27; 7():48. PubMed ID: 22452803
    [Abstract] [Full Text] [Related]

  • 9. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.
    Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S.
    Neoplasia; 2012 Jan 27; 14(1):34-43. PubMed ID: 22355272
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, Xie XJ, Bachoo R, Li L, Habib AA, Burma S.
    Clin Cancer Res; 2014 Mar 01; 20(5):1235-48. PubMed ID: 24366691
    [Abstract] [Full Text] [Related]

  • 11. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK.
    PLoS One; 2014 Mar 01; 9(4):e95588. PubMed ID: 24743574
    [Abstract] [Full Text] [Related]

  • 12. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Mar 01; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 13. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W, Fu W, Hu L.
    Cancer Biother Radiopharm; 2013 Nov 01; 28(9):665-73. PubMed ID: 23768063
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Nov 01; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 15. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
    Kim HJ, Gong MK, Yoon CY, Kang J, Yun M, Cho NH, Rha SY, Choi YD.
    Yonsei Med J; 2020 Jul 01; 61(7):587-596. PubMed ID: 32608202
    [Abstract] [Full Text] [Related]

  • 16. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL.
    Toxicol Lett; 2013 Jul 18; 220(3):267-76. PubMed ID: 23651616
    [Abstract] [Full Text] [Related]

  • 17. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.
    Int J Mol Med; 2013 Jun 18; 31(6):1449-56. PubMed ID: 23588698
    [Abstract] [Full Text] [Related]

  • 18. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Jun 18; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 19. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S, Leibowitz G, Riahi Y, Glaser B, Gross DJ, Grozinsky-Glasberg S.
    Neuroendocrinology; 2016 Jun 18; 103(6):724-37. PubMed ID: 26619207
    [Abstract] [Full Text] [Related]

  • 20. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.
    Mol Cancer; 2013 May 24; 12():46. PubMed ID: 23705826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.